Comparative Pharmacology
Head-to-head clinical analysis: AVINZA versus DOLENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVINZA versus DOLENE.
AVINZA vs DOLENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AVINZA (morphine sulfate) is a full opioid agonist that binds to mu-opioid receptors in the CNS, producing analgesia by altering pain perception and emotional response to pain.
Opioid agonist, primarily mu-opioid receptor activation, leading to analgesic and euphoric effects.
Oral, 30 mg once daily (q24h) for opioid-naïve patients; titrate based on response. Maximum daily dose 160 mg. Administer with food to minimize peak effects.
50 mg orally every 4-6 hours as needed for pain; maximum 400 mg per day.
None Documented
None Documented
Terminal elimination half-life of morphine is approximately 1.5-2 hours; however, due to the extended-release formulation, the effective half-life is prolonged to about 9-11 hours, allowing once-daily dosing.
2.5-3.5 hours; prolonged in hepatic impairment (up to 6-8 hours) and in neonates.
Primarily renal (approximately 90% as morphine metabolites, mainly morphine-3-glucuronide and morphine-6-glucuronide); biliary/fecal excretion accounts for less than 10%.
Renal: 70-80% as conjugated metabolites (mostly glucuronides), 5-10% as unchanged drug; Fecal: 5-10%; Biliary: minor.
Category C
Category C
Opioid Analgesic
Opioid Analgesic